Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
340.6 GBX | +0.71% | +4.80% | +5.25% |
May. 07 | AstraZeneca target raised; Antofagasta lowered | AN |
May. 01 | JPMorgan Lifts Rotork PT, Keeps Rating at Neutral | MT |
Sales 2024 * | 752M 941M | Sales 2025 * | 793M 993M | Capitalization | 2.92B 3.65B |
---|---|---|---|---|---|
Net income 2024 * | 118M 148M | Net income 2025 * | 134M 168M | EV / Sales 2024 * | 3.7 x |
Net cash position 2024 * | 134M 168M | Net cash position 2025 * | 187M 234M | EV / Sales 2025 * | 3.44 x |
P/E ratio 2024 * |
24.8
x | P/E ratio 2025 * |
21.8
x | Employees | 3,342 |
Yield 2024 * |
2.24% | Yield 2025 * |
2.4% | Free-Float | 99.4% |
Latest transcript on Rotork plc
1 day | +0.71% | ||
1 week | +4.80% | ||
Current month | +5.32% | ||
1 month | +4.41% | ||
3 months | +7.58% | ||
6 months | +11.16% | ||
Current year | +5.25% |
Managers | Title | Age | Since |
---|---|---|---|
Kiet Huynh
CEO | Chief Executive Officer | 45 | 17-12-31 |
Ross Pascoe
CTO | Chief Tech/Sci/R&D Officer | - | 22-11-30 |
Paul Burke
CTO | Chief Tech/Sci/R&D Officer | - | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Janice Stipp
BRD | Director/Board Member | 64 | 19-12-31 |
Dorothy Thompson
CHM | Chairman | 63 | 22-11-30 |
Timothy Cobbold
BRD | Director/Board Member | 61 | 18-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 0 M€ | -.--% | - | |
0.02% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 340.6 | +0.71% | 1,419,202 |
24-05-09 | 338.2 | +0.24% | 494,466 |
24-05-08 | 337.4 | +1.87% | 1,722,888 |
24-05-07 | 331.2 | +1.91% | 1,826,568 |
Delayed Quote London S.E., May 10, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.25% | 3.65B | |
-5.52% | 5.94B | |
-1.16% | 399M | |
+5.71% | 180M | |
-31.04% | 180M | |
-1.47% | 146M | |
+1.45% | 52.59M |
- Stock Market
- Equities
- ROR Stock